Wager J, Lunell N O, Nadal M, Ostman J
Acta Obstet Gynecol Scand. 1981;60(3):291-4. doi: 10.3109/00016348109158133.
Previous studies in pregnancy have shown that intravenous infusion of beta 2-sympathomimetic drugs, such as salbutamol, is followed by pronounced carbohydrate and lipid metabolic effects. Similar effects, though less pronounced, have also been demonstrated after oral salbutamol administration. Glucose elimination and insulin response after an intravenous glucose tolerance test (IVGTT) were analyzed in 12 women treated with oral salbutamol in the last trimester of pregnancy. IVGTT was performed without salbutamol and after at least 10 and up to 45 days of salbutamol treatment. No significant difference in either glucose elimination or insulin response to the glucose load were observed as a consequence of the salbutamol medication. This is in agreement with previous studies of other beta 2-sympathomimetic drugs and indicates that the use of salbutamol in late pregnancy does not give rise to serious disturbances of carbohydrate metabolism in healthy women.
先前针对孕期的研究表明,静脉输注β2-拟交感神经药物(如沙丁胺醇)后,会出现明显的碳水化合物和脂质代谢效应。口服沙丁胺醇后也出现了类似效应,尽管不太明显。对12名在妊娠晚期接受口服沙丁胺醇治疗的女性进行了静脉葡萄糖耐量试验(IVGTT),分析了葡萄糖清除率和胰岛素反应。IVGTT在未使用沙丁胺醇时以及在沙丁胺醇治疗至少10天至45天后进行。沙丁胺醇用药后,未观察到葡萄糖清除率或对葡萄糖负荷的胰岛素反应有显著差异。这与先前对其他β2-拟交感神经药物的研究结果一致,表明在妊娠晚期使用沙丁胺醇不会导致健康女性出现严重的碳水化合物代谢紊乱。